27/12/2017 Gadolinium-based contrast agents: FDA Requirements December 2017 Guerbet LLC Update

Gadolinium-based contrast agents: update from Guerbet LLC on U.S. Food and Drug Administration (FDA) requirements


24/10/2017 FDA Approves Guerbet’s Dotarem® (gadoterate meglumine) for Pediatric Patients Younger Than Two Years

Princeton (NJ, USA), September 5, 2017 Guerbet LLC USA, the US affiliate of the global specialist in contract products and solutions for medical imaging, announced today that the US Food and Drug Administration (FDA) has approved Dotarem® (gadoterate meglumine) for intravenous use with magnetic...


08/09/2017 Guerbet Statement Following Medical Imaging Drugs Advisory Committee September 8, 2017

Princeton (NJ, USA) Magnetic resonance imaging (MRI) is a widely used diagnostic procedure which is critical to patient health. And vital to MRI are the contrast agents that give physicians a sharper, more accurate picture of tissue than they would otherwise be able to have.  There are two...


24/06/2016 Guerbet Honored With Supplier Horizon Award from Premier Inc.

Princeton, NJ, 23 June 2016 – Guerbet announced that it has been named a winner of Premier Inc.’s Supplier Horizon Award


29/09/2014 Guerbet Receives FDA’s Drug Shortage Assistance Award

Guerbet LLC, USA (September 29, 2014)


Displaying results ###SPAN_BEGIN###%s to %s out of ###SPAN_BEGIN###%s